

CITATION REPORT

List of articles citing

Clinical trials on drug repositioning for COVID-19 treatment

DOI: 10.26633/rpsp.2020.40

Revista Panamericana De Salud Publica/Pan American
Journal of Public Health, 2020, 44, e40.

Source: <https://exaly.com/paper-pdf/76623376/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
265	In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. 2020 , 15, e0240149		31
264	Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. 2020 , 1-17		8
263	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. 2020 , 13, 255-260		12
262	Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study. 2020 , 11, 560209		11
261	Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. 2020 , 290, 198169		23
260	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. 2020 , 887, 173568		2
259	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. 2020 , 259, 118275		44
258	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721		63
257	The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. 2020 , 96, 1187-1208		49
256	Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL). 2021 , 39, 5735-5755		26
255	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787		11
254	COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. 2020 , 14, 5097-5108		4
253	Drug Repurposing (DR): An Emerging Approach in Drug Discovery. 2020 ,		24
252	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 606393	5.6	17
251	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,		16
250	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. 2020 , 884, 173381		9
249	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. 2020 , 144, 111639		28

248	Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physicianB perspective. 2020 , 13, 45		5
247	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. <i>RSC Advances</i> , 2020 , 10, 28243-28266	3-7	25
246	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. 2020 , 56, 106119		24
245	Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. <i>BMJ Open</i> , 2020 , 10, e039730	3	18
244	Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study. 2021 , 39, 6713-6727		13
243	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. 2020 , 12,		52
242	Potential diagnostics and therapeutic approaches in COVID-19. 2020 , 510, 488-497		25
241	A scientificity and feasibility evaluation of COVID-19 clinical studies registered in China. 2020 , 8, 817		2
240	A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019. 2020 , 99, e21402		2
239	Medical Nutrition Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection in a Non-critical Care Setting: Knowledge in Progress. 2020 , 9, 309-315		7
238	Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from to combat COVID19: study. 2020 , 1-13		12
237	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). 2020 , 16, 933-946		4
236	Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay. 2020 , 89, 107408		23
235	Repositioning and investigational drugs for Zika virus infection treatment: a patent review. 2020 , 30, 847-862		1
234	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. 2020 , 25,		46
233	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508		165
232	Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Method. 2020 , 25,		36
231	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131		2

230	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
229	Pharmacological treatments of COVID-19. 2020 , 72, 1446-1478	16
228	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. 2020 , 8,	10
227	Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic. 2020 , 7, 598038	4
226	Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. 2020 , 22, 28115-28122	18
225	Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. 2020 , 75, 2016-2017	2
224	An Update on Current Therapeutic Drugs Treating COVID-19. 2020 , 6, 1-15	300
223	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. 2020 , 11, 245-268	69
222	Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation. 2020 , 11, 796	9
221	Artificial intelligence approach fighting COVID-19 with repurposing drugs. 2020 , 43, 355-362	105
220	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
219	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. 2020 , 68, 93-104	13
218	Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. 2020 , 31, 179-193	79
217	Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target. 2020 , 882, 173237	1
216	A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). 2020 , 40, 101214	58
215	Optical theranostics and treatment dosimetry for COVID-19 lung complications: Towards increasing the survival rate of vulnerable populations. 2020 , 31, 101892	6
214	Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. 2021 , 39, 4633-4646	33
213	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829	3

212	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. 2020 , 75, 2775-2793	13
211	Pirfenidone: A novel hypothetical treatment for COVID-19. 2020 , 144, 110005	30
210	In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme. 2021 , 39, 5290-5303	12
209	COVID-19 and the Drug Repurposing Tsunami. 2020 , 18, 211-214	9
208	Emerging Prevention and Treatment Strategies to Control COVID-19. 2020 , 9,	19
207	When science goes viral: The research response during three months of the COVID-19 outbreak. 2020 , 129, 110451	34
206	Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. 2020 , 13,	39
205	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. 2020 , 144, 47-53	86
204	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. 2020 , 9,	87
203	Overview of transnational recommendations for COVID-19 transmission control in dental care settings. 2021 , 27 Suppl 3, 655-664	53
202	Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises. 2021 , 17, 163-175	44
201	A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs. 2021 , 35, 205-214	13
200	Potential role of interferons in treating COVID-19 patients. 2021 , 90, 107171	36
199	Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. 2021 , 224, 121862	23
198	Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. 2021 , 44, 43-53	16
197	Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19. 2021 , 17, 33-43	51
196	Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. 2021 , 68, 318-332	4
195	SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28	5

194	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. 2021 , 183, 114296		44
193	Exploring the magic bullets to identify AchillesRheel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. 2021 , 147, 111887		6
192	The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. <i>Microbial Pathogenesis</i> , 2021 , 150, 104673	3.8	45
191	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753		28
190	Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. 2021 , 420, 117263		36
189	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 585899	5.6	6
188	Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition. 2021 , 35, 908-919		7
187	Potential small-molecule drugs as available weapons to fight novel coronavirus (2019-nCoV): A review. 2021 , 39, 4-9		6
186	Immune response and possible therapeutics in COVID-19.. <i>RSC Advances</i> , 2020 , 11, 960-977	3.7	2
185	Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. 2021 , 4, 93		71
184	Prospecting for to treat COVID-19 via molecular docking models of the SARS-CoV-2. 2021 , 1-10		8
183	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. 2021 , 21, 3-9		4
182	Dual targeting of 3CL and PL of SARS-CoV-2: A novel structure-based design approach to treat COVID-19. 2021 , 3, 9-18		17
181	The Main Sources and Potential Effects of COVID-19-Related Discrimination. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1318, 705-725	3.6	4
180	In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. 2021 , 40, 296-309		28
179	A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. 2021 , 26, 2515690X211003727		1
178	Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China. 2021 , 15, e0009051		5
177	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89		

176	The potential role of Fluoroquinolones in the management of Covid-19 a rapid review. 2021 , 11, 128-134	9
175	Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021 , 36, 1646-1650	22
174	Recent biotechnological advances as potential intervention strategies against COVID-19. 2021 , 11, 41	5
173	Identification of potential antivirals against SARS-CoV-2 using virtual screening method. 2021 , 23, 100531	8
172	Medicinal Plants with Potential Inhibitory Bioactive Compounds against Coronaviruses.. 2022 , 12, 7-16	0
171	Functional capacity and rehabilitation strategies in Covid-19 patients: current knowledge and challenges. 2021 , 54, e07892020	5
170	Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2. 2021 , 19, 424-438	14
169	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5	8
168	Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections. <i>Viruses</i> , 2021 , 13,	6.2 11
167	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. 2021 , 25, 1905-1927	8
166	A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation. 2021 , 22, 1476-1498	31
165	Cross Talk between COVID-19 and Breast Cancer. 2021 , 21, 575-600	4
164	Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19. 2021 , 121, e26617	23
163	Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. 2021 , 21, 275-284	11
162	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. 2021 , 12, 576448	5
161	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7
160	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. 2021 ,	0
159	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. 2021 , 895, 173890	41

158	Environmental aspect and applications of nanotechnology to eliminate COVID-19 epidemiology risk. 2021 , 6, 1		1
157	Potential therapeutic and pharmacological strategies for SARS-CoV2. 2021 , 51, 1-16		9
156	A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. 2021 , 35, e21360		14
155	COVID-19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25		127
154	Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight. 2021 , 22, 192-199		2
153	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. 2021 , 897, 173947		31
152	Therapeutic Agents for COVID-19: an Overview. 2021 , 16, 22-44		1
151	The use of medicinal plants to prevent COVID-19 in Nepal. 2021 , 17, 26		26
150	The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19. 2021 , 27, 1202-1210	o	
149	Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro. <i>Viruses</i> , 2021 , 13,	6.2	2
148	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. 2021 , 2021, 6631721		11
147	Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. 2021 , 16, e0250147		11
146	Rutin: A Potential Antiviral for Repurposing as a SARS-CoV-2 Main Protease (Mpro) Inhibitor. 2021 , 16, 1934578X2199172		5
145	Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs. 2021 , 105, 3457-3470		3
144	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. 2021 , 28, 2114-2136		2
143	Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence. 2021 , 27, 1153-1169		3
142	Coronavirus Disease 2019: An Overview of the Complications and Management. 1-28		
141	The Emergence of Novel Coronavirus Disease, Global Treatment Update and its Containment Strategies in Overpopulated Countries: A Review. <i>Coronaviruses</i> , 2021 , 2,		1.5

140	COVID-19: breaking down a global health crisis. 2021 , 20, 35		43
139	An Examination of COVID-19 Medications Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review. 2021 , 9,		1
138	Existing Drugs Considered as Promising in COVID-19 Therapy. 2021 , 22,		9
137	An update review of emerging small-molecule therapeutic options for COVID-19. 2021 , 137, 111313		26
136	Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. 2021 , 17, 2824-2840		3
135	Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. 2021 , 13, 184-202		1
134	Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. 2021 , 2, 100011		10
133	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. <i>Infectious Disorders - Drug Targets</i> , 2021 , 21, 514-526	1.1	5
132	Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development.		1
131	Simplified process of candidate certified reference material development for the analysis of <i>Andrographis paniculata</i> derived therapeutics. 2021 , 165, 106140		0
130	COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. 2021 , 18,		
129	The pulmonary route as a way to drug repositioning in COVID-19 therapy. 2021 , 63, 102430		2
128	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. 2021 , 18, e1003660		8
127	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. 2021 ,		12
126	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <i>Carbohydrate Research</i> , 2021 , 505, 108326	2.9	19
125	Emetine, a potent alkaloid for the treatment of SARS-CoV-2 targeting papain-like protease and non-structural proteins: pharmacokinetics, molecular docking and dynamic studies. 2021 , 1-14		4
124	Diagnosis, prevention, and treatment of coronavirus disease: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 1-24	5.5	1
123	Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic. 2021 , 11,		6

122	Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19. 2021 , 18, 583-595	4
121	Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings. 2021 , 18, e2100336	0
120	A fuzzy logic-based computational method for the repurposing of drugs against COVID-19. 2021 ,	0
119	Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19. 2021 , 136, 104686	5
118	A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2. 2021 , 32,	4
117	Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications. 2021 , 14,	3
116	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. 2021 , 1, 252-284	7
115	COVID-19, cytokines, inflammation, and spices: How are they related?. 2021 , 284, 119201	15
114	COVID-19 THERAPEUTICAL OPTIONS: OVERVIEW ON CURRENTLY ANTIMALARIALS AND ANTIPARASITIC DRUGS USED. 2021 ,	
113	Emerging Potential of Metallodrugs to Target Coronavirus: Efficacy, Toxicity and their Mechanism of Action. 2021 , 33, 1191-1207	0
112	Pandemic Supply Chain Research: A Structured Literature Review and Bibliometric Network Analysis. 2021 , 5, 7	10
111	Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review. 2021 , 44, 386-398	3
110	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. 2021 , 12, 155-191	13
109	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. 2021 , 2, 100026	4
108	Impact of repurposed drugs on the symptomatic COVID-19 patients. 2021 , 14, 24-38	3
107	COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. <i>Viruses</i> , 2021 , 13,	6.2 52
106	Recent progress in the development of potential drugs against SARS-CoV-2. 2021 , 2, 100057	0
105	Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. 2020 , 4, 263-274	3

104	Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. 2020 , 289, 198146	20
103	Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study.	9
102	Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing.	2
101	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. 2020 , 58, 2047-2061	4
100	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. 2020 , 8, e121	9
99	Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease. 2020 , 53, e20200472	3
98	Prospects for a COVID-19 treatment: review. 2020 , 7, 30-37	5
97	Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. 2021 , 28, 2392-2408	6
96	The Use of Cyclodextrin or its Complexes as a Potential Treatment Against the 2019 Novel Coronavirus: A Mini-Review. 2021 , 18, 382-386	5
95	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. 2020 , 8, e21648	5
94	COVID-19 pandemic and cardiovascular disease: where do we stand?. 2020 , 68, 347-358	7
93	Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?. 2020 , 111, 362-364	3
92	Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. 2021 , 71, 163-174	15
91	Drug Repositioning for COVID-19. 2020 , 51, e4279	3
90	The effect of COVID-19 on global population and its fatality rate: Retrospective study by online database. 72, 13-16	3
89	COVID-19 in Latin America: A Bibliometric Analysis of Scientific Publications in Health. 2020 , 17, em261	8
88	Clinical Characteristics and Mortality Predictors of COVID-19 Patients Hospitalized at Nationally-Designated Treatment Hospitals. 2020 , 35, e328	23
87	Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. 2020 , 11, 590598	8

86	Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. 2020 , 21,	25
85	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. 2020 , 21,	25
84	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). 2021 , 58, 145-157	32
83	Perspectives for repurposing drugs for the coronavirus disease 2019. 2020 , 151, 160-171	37
82	Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis. 2020 , 16, 301-306	22
81	Computerized monitoring of COVID-19 trials, studies and registries in ClinicalTrials.gov registry. 2020 , 8, e10261	2
80	Contributions of Latin American researchers in the understanding of the novel coronavirus outbreak: a literature review. 2020 , 8, e9332	10
79	Integrative COVID-19 biological network inference with probabilistic core decomposition. 2021 ,	1
78	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. 2021 ,	1
77	A Comprehensive Overview of the Newly Emerged COVID-19 Pandemic: Features, Origin, Genomics, Epidemiology, Treatment, and Prevention. 2021 , 1, 357-383	5
76	Current trends in diagnosis and treatment strategies of COVID-19 infection. 2021 , 28, 64987-65013	2
75	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. 2021 , 28, 68071	4
74	At a glance on Coronavirus Disease (COVID-19): Pathogenesis, Innate and acquired mechanisms, Host-virus genomes interactions, Therapeutic options and prevention (Preprint).	
73	A systematic review protocol of the antiviral activity of chloroquine and hydroxychloroquine against COVID-19.	
72	Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.	
71	As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. 2020 , 1, 1-18	
70	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach (Preprint).	
69	Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. 2021 , 22,	7

68	Sophorolipid: A glycolipid biosurfactant as a potential therapeutic agent against COVID-19. 2021 ,		2
67	Ionizing Radiation as a Non-invasive Treatment for COVID-19 Patients-A Perspective Review. 596, 012036		0
66	Therapeutic options in SARS-CoV-2 infection. 2020 , 4, 14		
65	Infecci3n por SARS-CoV-2 (COVID-19) en Pediatr3a. <i>Revista Latinoamericana De Infectolog3a Ped3trica</i> , 2020 , 33, 191-203		0.1
64	TREATMENT PROFILES AND CLINICAL OUTCOMES OF COVID-19 PATIENTS AT PRIVATE HOSPITAL IN JAKARTA.		
63	Broad-spectrum antiviral activity of 3D8, a nucleic acid-hydrolyzing single chain variable fragment (scFv), targeting SARS-CoV-2 and multiple coronaviruses in vitro.		
62	Treatment of People with Evans Syndrome in the Setting of COVID-19 Pandemic. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2020 , 1, 160-162		0.3
61	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. <i>Acta Cardiologica Sinica</i> , 2021 , 37, 9-17	1.1	1
60	Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application. <i>Journal of Clinical and Translational Research</i> , 2021 , 7, 127-139	1.1	1
59	Computational methods directed towards drug repurposing for COVID-19: advantages and limitations.. <i>RSC Advances</i> , 2021 , 11, 36181-36198	3.7	2
58	Identification of raloxifene as a novel β -glucosidase inhibitor using a systematic drug repurposing approach in combination with cross molecular docking-based virtual screening and experimental verification. <i>Carbohydrate Research</i> , 2021 , 511, 108478	2.9	1
57	An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro. <i>Scientific Reports</i> , 2021 , 11, 22796	4.9	3
56	Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors. <i>Frontiers in Endocrinology</i> , 2021 , 12, 711906	5.7	1
55	Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia.. <i>Vaccines</i> , 2021 , 9,	5.3	2
54	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <i>Future Microbiology</i> , 2021 , 16, 1415-1451	2.9	1
53	The Effect of Spiritual Practice along with Routine Medical Care on the Recovery of Patients Hospitalized with Covid-19: a Randomized Clinical Trial. <i>Iranian Journal of War and Public Health</i> , 2020 , 12, 213-221	0.1	
52	Chapter 4. Role of Industry. <i>RSC Drug Discovery Series</i> , 2022 , 52-73	0.6	
51	Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 53, 116523	3.4	1

50	Current Challenges for the Effective Management of the COVID-19 Pandemic.. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1353, 131-149	3.6	0
49	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2021 , 7, 28-70	0.1	
48	COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.. <i>Viruses</i> , 2022 , 14,	6.2	5
47	An update review on complicated mechanisms of COVID-19 pathogenesis and therapy: direct viral damage, renin-angiotensin system dysregulation, immune system derangements, and endothelial dysfunction.. <i>Infectious Disorders - Drug Targets</i> , 2022 ,	1.1	1
46	Recent advances in understanding SARS-CoV-2 infection and updates on potential diagnostic and therapeutics for COVID-19. <i>Coronaviruses</i> , 2022 , 03,	1.5	
45	Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 781039	5.6	1
44	Curcumin and Its Analogs as a Therapeutic Strategy in Infections Caused by RNA Genome Viruses.. <i>Food and Environmental Virology</i> , 2022 , 1	4	2
43	Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.. <i>BMJ Open</i> , 2021 , 11, e050051	3	0
42	Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX α Reductase B as a Novel Thrombocytopenia Therapeutic Target.. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	
41	COVID-19: The question of genetic diversity and therapeutic intervention approaches.. <i>Genetics and Molecular Biology</i> , 2021 , 44, e20200452	2	0
40	COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials. <i>Journal of Advances in Medical and Biomedical Research</i> , 2022 , 30, 75-85	0.4	
39	Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?.. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022 , 37, 1077-1082	5.6	2
38	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission.. <i>Epidemics</i> , 2022 , 39, 100567	5.1	
37	datasheet1.pdf. 2020 ,		
36	image1.jpeg. 2020 ,		
35	table1.xlsx. 2020 ,		
34	table2.xlsx. 2020 ,		
33	Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021 , 20, 1-8	1.1	0

32	Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease. <i>Archives of Razi Institute</i> , 2021 , 76, 453-459	0.6	2
31	Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.. <i>Journal of Clinical and Translational Research</i> , 2022 , 8, 125-137	1.1	
30	IDENTIFY THE CURRENT TRENDS RELATED TO THE TREATMENT AND PREVENTION OF COVID- 19. 2022 , 1, 17-21		
29	Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation. <i>Frontiers in Microbiology</i> , 2022 , 13,	5.7	0
28	Drug repurposing for the treatment of COVID-19. <i>Journal of Pharmacological Sciences</i> , 2022 , 149, 108-114	1.7	1
27	Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.. <i>Journal of Clinical and Translational Research</i> , 2022 , 8, 127-146	1.1	0
26	Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability. <i>Expert Review of Anti-Infective Therapy</i> ,	5.5	
25	Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease. <i>Structural Chemistry</i> ,	1.8	
24	Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. <i>Pharmaceutical Patent Analyst</i> ,	0.6	
23	In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing. <i>Dr Sulaiman Al Habib Medical Journal</i> ,	1.4	
22	Vitamin C and its therapeutic potential in the management of COVID19. <i>Clinical Nutrition ESPEN</i> , 2022 ,	1.3	2
21	Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. <i>Microbial Pathogenesis</i> , 2022 , 168, 105608	3.8	0
20	Analysis of the Adomian decomposition method to estimate the COVID-19 pandemic. 2022 , 173-187		
19	Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era. <i>National Science Review</i> ,	10.8	0
18	Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery. <i>Archiv Der Pharmazie</i> ,	4.3	1
17	COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. <i>Research Journal of Pharmacy and Technology</i> , 2022 , 2862-2868	1.7	
16	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.		0
15	Hepatotoxicity in Patients Using Favipiravir for COVID-19: A Retrospective Study. 2022 , 3, 92-98		

14	Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. 2022 , 23, 9136	5
13	Biotechnological Strategies in the Intervention and Treatment of COVID-19. 2022 , 421-442	0
12	Nanocarriers as delivery tool for COVID-19 drugs. 2022 , 293-332	1
11	Bibliometric Analysis of Published Literature on the Pharmaceutical Supply Chain. 2022 , 12, 1-18	0
10	Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.	4
9	Drug repositioning: A bibliometric analysis. 13,	1
8	COVID-19: Clinical status of vaccine development till date.	0
7	Repurposing of Drugs: Updates and New Perspectives. 2022 , 4309-4314	0
6	Exploring NFkB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality. 2022 , 13,	0
5	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. 2023 , 16, 233-249	0
4	Investigation of aluminum nitride nanocarrier for drug delivery process of Favipiravir: A DFT study. 2023 , 372, 121209	0
3	Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in silico studies and antiviral assays. 2023 , 234, 123540	0
2	Drug Repurposing: An Approach for Reducing Multidrug Resistance. 2023 , 179-190	0
1	State-of-the-Art Review on the Models, Techniques, and Datasets to Diagnose COVID-19 Disease. 2023 , 208-233	0